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Abstract: Excessive UV exposure contributes to several pathological conditions like skin burns, 
erythema, premature skin aging, photodermatoses, immunosuppression, and skin carcinogenesis. 
Effective protection from UV radiation may be achieved with the use of sunscreens containing UV 
filters. Currently used UV filters are characterized by some limitations including systemic absorption, 
endocrine disruption, skin allergy induction, and cytotoxicity. In the research centers all over the 
world new molecules are developed to improve the safety, photostability, solubility, and absorption 
profile of new derivatives. In our study, we designed and synthesized seventeen novel molecules by 
combining in the structures two chromophores: xanthone and (E)-cinnamoyl moiety. The ultraviolet 
spectroscopic properties of the tested compounds were confirmed in chloroform solutions. They acted 
as UVB or UVA/UVB absorbers. The most promising compound 9 (6-methoxy-9-oxo-9H-xanthen-2- 
yl)methyl (E)-3-(2,4-dimethoxyphenyl)acrylate) absorbed UV radiation in the range 290-369 nm. Its 
photoprotective activity and functional photostability were further evaluated after wet milling and 
incorporation in the cream base. This tested formulation with compound 9 possessed very beneficial 
UV protection parameters (SPFin vitro of 19.69 ±  0.46 and UVA PF of 12.64 ±  0.32) which were similar 
as broad-spectrum UV filter tris-biphenyl triazine. Additionally, compound 9 was characterized by 
high values of critical wavelength (381 nm) and UVA/UVB ratio (0.830) thus it was a good candidate 
for broad-spectrum UV filter and it might protect skin against UVA-induced photoaging. Compound 
9 were also shown to be photostable, non-cytotoxic at concentrations up to 50 pM when tested on 
five cell lines, and non-mutagenic in Ames test. It also possessed no estrogenic activity, according to 
the results of MCF-7 breast cancer model. Additionally, its favorable lipophilicity (miLogP = 5.62) 
does not predispose it to penetrate across the skin after topical application.
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1. Introduction
Ultraviolet radiation (UVR) detected on Earth significantly affects all living organisms 
including humans. Apart from positive effects of the reasonable UVR exposure, e.g., 
vitamin D production, several pathological conditions like skin burns, erythema, premature
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skin aging, photodermatoses, immunosuppression, and skin carcinogenesis were identified 
as results of extensive UVR exposure [1- 3]. In order to provide effective protection from 
UV radiation, sunscreen preparations containing UV filters are recommended. Currently 
used UV filters are characterized by many drawbacks such as interrupting of endocrine 
system, skin allergic reactions, and cytotoxicity [2,4- 6]. Further attempts are made all over 
the world to discover novel molecules which would provide effective UV protection with 
minimum adverse side effects.
One of the strategies in the development of new UV filter molecules is the modification 
of well-known sunscreens by means of multiplying the chromophore and by incorporation 
of additional auxochromes or alkyl groups. These modifications are intended to improve 
safety, photostability, solubility, and absorption profile of new derivatives. For example, 
the molecule of ethylhexyl triazone approved in the late 1990s contains three molecules 
of PABA (para-aminobenzoic acid) linked to a triazine ring. The chromophore used in 
triplicate allowed to obtain broad absorption profile and high molecular weight that 
prevent penetration through the skin [7,8]. Bino et al. focused on the modification of
2-phenyl-1H-benzimidazole-5-sulfomc acid by incorporating additional functional groups 
in phenyl and benzimidazole rings to obtain molecules able to act as UV absorbers and 
inhibitors of radical species formation [9]. In our recent study, we designed new UV 
filters based on the structure of 3-benzylidene camphor. In our compounds, the camphor 
fragment was replaced with the imidazolidine-2,4-dione moiety with the aim of improving 
safety, the incorporation of allyl group contributed to the extension of the UV absorption, 
whereas 2-ethoxy-2-oxoethyl substituents in the imidazolidine ring improved the solubility 
of molecules [10 ].
Cinnamates are widely used in cosmetics, not only as UV filters or UV absorbers but 
also as skin and hair conditioners, antioxidants, perfuming, masking, and antimicrobial in­
gredients [11]. UV filters that are (E)-cmnamoyl derivatives have been approved in selected 
countries all over the world: octinoxate (INCI: Ethylhexyl methoxycinnamate, EHMC), amilox- 
ate (INCI: Isoamyl p-methoxycinnamate), octocrylene, cinoxate, diethanolamine methoxycin- 
namate, 2 ,5-diisopropyl methyl cinnamate, and isopentyl trimethoxycinnamate trisilox- 
ane [12,13]. Octinoxate (Figure 1a) is ethylhexyl ester of 4-methoxycinnamic acid, its 
structure allows electron delocalization required for absorbance in UVB region and is 
typical for UV filters— constitutes disubstituted aromatic molecule with electron releasing 
(-OCH3) and electron accepting (ester group) substituents. Electron releasing group is 
in para position to the carbonyl group which is additionally conjugated with a double 
bond [14]. Octocrylene (Figure 1b) is ethylhexyl ester of 2-cyano-3,3-diphenylacrylic acid, 
this compound is characterized by relatively low extinction coefficient but has an excellent 
photostability and is used as photostabilizer of other UV filters [15]. Absorption range 
of cinnamates is narrow, they provide protection only in UVB region, moreover EHMC 
upon irradiation undergoes trans-cis isomerization which results in absorption loss [16]. 
Therefore, the aim of our study was to design new potential UV filters by modifications 
of (E )-cinnamic acid derivatives to obtain new, safe, broad absorbing and photostable 
compounds. We decided to combine (E)-cinnamoyl moiety with another chromophore— 
xanthone skeleton.
Xanthone (dibenzo-y-pyrone) possesses conjugated double bond system and several 
potential substitution positions. Coupling with an appropriate auxochromic groups and 
additional chromophores gives the opportunity to select substances not only with the 
intended photoprotectiveness in a wide UV range but also with a satisfactory safety profile. 
Xanthone derivatives have been subject of multidirectional research for many years. A 
lot of them have a favorable biological and pharmacological activity profile, including 
among other antioxidant [17], antimicrobial [18], anticancer [19,20], and anti-inflammatory 
effect [21]. Moreover, xanthone derivatives have also recently been of interest in the field of 
cosmetics chemistry. Mangiferin (2-ß-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen- 
9-one, Figure 2) and its derivatives are of particular interest, its cosmetic application is the 
subject of many patents claims [22]. Moreover in in vivo study mangiferin was shown to
inhibit UVB-induced length and depth of skin wrinkles. Additionally, mangiferin improves 
the photostability of avobenzone and reduces its phototoxic potential [23,24],
Figu re 1. The chemical structures of octinoxate (INCI: Ethylhexyl methoxycinnamate) (a) and octocrylene (b).
In the present study, we designed and synthesized novel derivatives combining in the 
structures the two above mentioned chromophores: xanthone and (E)-cinnamoyl moiety 
(Figure 3). "We intended lo obtain compounds characterized by lipophilicity predisposing 
for affinity to stratum corneum rather than penetrating into deeper layers of the skin. Aport 
from UV absorption properties, we aimed to incorporate the most promising compounds 
into cosmetic formulation to evaluate their photoprotective aotivity and photostability 
in the conditions of future use. Additionallp, with in viCro methods we assessed their 
safety profile in mutagenic and estrogenic activity assays. We also performed tests of 
their cytotoxicity in ktratieocytes and skin fibroblasts as well as ia hepatocytts, astrocytes 
and cardiomyoblastc.
Figure 2. The chemical structure of mangiferin.
Figure 3. The design concepit of the novel UV filters: combinaeon of xanthone and (El-ennamoyl chromophores.
2. Results and Discussion
2.1. Cłiemistr.
Chami cal structures of tested compounds were shown in Tible 1 and tOe route of thoir 
synthes in was presented in Schemes 1, 2, 3 .
Compound Rj Position of R2 R? miLogP’ '■MO
6.16 5.02
6.383 5.28
6.19 5.66
6.42 5.06
5.57 5.10
5.77 4.96
5.79 5.06
5.82 6.15
5.62 4.64
5.41 4.53
5.334 4.50
7.10 5.62
Table 1. Chemical structures and lipophilicity parameters of tested compounds.
1 H 4­
2 H 4­
3 6-OCH3  4­
4 6-OCH3  4­
5 6-OCH3  4­
6 6-OCH3  4­
7 6-OCH3  4­
8 6-OCH3  2­
9 6-OCH3  2­
10 6-OCH3  2­
1 1  6-OC133 2­
12  6-OCH3  2-
Table 1. Cont.
Compound R1 Position of R2 R2 miLogP * VM0
13 7-Cl 2- 6.-44 4.85
14
15
H
H
2- 6.1 4
5.2 4
5.1-
4.
16
17
H
H
3- 5.74
5.21
4.54
4.25
* calculated LogP values by Molispiration on-line tool, ** relative lipophilMty parameter determined 
by reversed-phase thm-layer chromatography.
Ri= H, f5-OCH3 ĉ l 7-CI 
R2 = 2-C42E-r or 4-CH2Br
R3 = H,2-CI, 4-C 1,2-OHH3, 3-OCH3, 4-PCH3,H,4-(OCH2)2, 3,0-(OHC322 ot=,3,4-(OCU-)3 
R.4^ H or p henyl
Scheme 1. Genedal route o- synthesis of compounds 1-13.
Scheme 2. General route of synthesis of compound 1-4.
R= H, 6-OCH3 or 7-CI
Scheme 3. (.1 eneral route of synthesis of compoundt 15-17.
2-
4-
Synthesis of starting materials for preparation of compounds 1-13, i.e., 4-(bromomethyl)- 
9H-xanthen-9-one [25], 2-(bromomethyl)-6-methoxy-9H-xanthen-9-one [26], 5-(bromomethyl)-
3-methoxy-9H-xanthen-9-one [19] and 2-(bromomethyl)-7-chloro-9H-xanthen-9-one [27] 
was performed according to previously published procedures. These compounds were 
further used in the reaction with appropriate derivatives of (E)-cinnamic acid in DMF 
in the presence of anhydrous K2CO3 as a proton acceptor resulting in obtaining of com­
pounds 1-13 (Scheme 1). Substrates for synthesis of compounds 14-17, i.e., 2 -, 3-, or
4-hydroxy-9H-xanthen-9-one [28- 31] and 2-(3-bromopropoxy)-9H-xanthen-9-one [32] were 
also synthesized according to available literature. 2-(3-Bromopropoxy)-9H-xanthen-9-one 
was further used in the reaction with (E)-4-methoxycinnamic acid to synthesize compound 
14 (Scheme 2 ). 2 -, 3-, or 4-hydroxy-9H -xanthen-9-ones were used in the reaction with 
(E)-cinnamoyl chloride to synthesize compounds 15-17 (Scheme 3). Chemical structures 
and purity of final compounds were confirmed by spectral analysis (NMR, L C /M S/M S).
2.2. Lipophilicity Evaluation
The relative lipophilicity parameters (RM0) of the tested compounds were determined 
using reversed-phase thin-layer chromatography (RP-TLC) according to previously pub­
lished procedures [33,34]. The investigations were carried on RP-18-coated aluminum 
sheets with mobile phase consisting of diverse concentrations of methanol and potassium 
phosphate buffer (pH = 7.4). The experimental data showed a linear correlation between 
RM values and the concentration of methanol, the obtained correlation coefficients ranged 
from 0.956 to 0.996 (Table S2 Supplementary Materials). The relative lipophilicity values 
(Rmo) of the tested compounds, calculated as extrapolations of Rm for 0% methanol concen­
trations, ranged from 4.19 to 6.15 (Table 1). We also calculated LogP values by Molispiration 
on-line tool [35] and provided results in Table 1 . The calculated values of miLogP ranged 
from 5.21 to 7.10.
Previous studies showed that lipophilicity was an important parameter of the molecule 
affecting the possibility of skin permeation. Compounds with logP of 4 -5  were character­
ized by poor permeation rate across the skin, while compounds with more hydrophilic 
nature (logP = 0-2.5) were predisposed to effective skin permeation after topical applica­
tion [36]. Similarly, according to formal guidance for the testing of cosmetic ingredients, 
substances with logP >  4 were characterized by very low dermal absorption [37]. Based on 
the performed lipophilicity evaluation, reported here UV filters would not penetrate across 
the skin after topical application.
2.3. Ultraviolet Spectroscopic Properties
The results of studies on the ultraviolet spectroscopic properties of the tested com­
pounds and reference UV filters were presented in Table 2 . This type of screening using 
low-concentrated compound solutions is very useful in the initial phase of searching for 
new UV filter candidates and is aimed at identification of structures for more advanced tests. 
Among presented group of (E )-cinnamoyl xanthone derivatives, all tested compounds 
might be characterized as ultraviolet radiation absorbers. UV spectroscopic properties of 
some of them surpass commercially available UV filters such us 3-(4-methyl)benzylidene 
camphor (4-MBC), octocrylene (OCT), octinoxate (EHMC) and avobenzone (BMDM). 
Compound 1 showed the weakest absorption properties. This compound is deprived 
of 6-methoxy group in xanthone skeleton additionally chloro substituent is located in 
ortho position of phenyl ring of trans-cinnamoyl residue. Compound 2 with chlorine 
atom in para position was characterized by much higher molar extinction coefficient in 
comparison to the compound 1, whereas compound 4 with both chlorine atom in para 
position and 6-methoxy group in xanthone skeleton showed not only higher £max and 
<Ex,1 >mean value than compounds 1-3 but also bathochromic shift by 6 nm. Ultraviolet 
spectroscopic properties of compounds 7 and 8 were very similar which indicated that 
position of methoxycinnamoyl substituent in xanthone ring did not significantly affect their 
UV absorption properties. The Amax of these compounds (300 and 303 nm, respectively),
similarly to EHMC, was located in UVB region, additionally their £max, <Ei,i>mean and 
absorption range were much higher in comparison to the reference UVB filters (Figure 
4). E(1,1) value as well as molecular mass are often used to present UV filters properties. 
Reported here (E)-cinnamoyl xanthone derivatives possessed high molar mass, which is 
desirable from modern UV filters, therefore despite much higher £max for compounds 7 
and 8 in comparison to the EHMC and 4-MBC, their E(1,1) values were similar.
Table 2. Ultraviolet spectroscopic properties of the tested xanthone derivatives and reference UV 
filters obtained in chloroform solutions.
Compound Absorption Range (nm) Amax (nm)
1 290-352 290
2 290-351 290
3 290-342 290
4 290-341 296
5 290-350 290
6 290-342 290
7 290-346 300
8 290-348 303
9 290-369 299, 329
10 290-355 301, 326
1 1 290-354 304
12 290-340 299
13 290-359 312
14 290-375 300
15 290-355 290
16 290-345 290
17 290-351 290
4-MBC 290-328 300
OCT 290-347 306
EHMC 290-337 309
BMDM 290-391 357
emax (M- 1  cm-1) <El,1 >mean
15,311 392 69
25,688 657 133
27,690 658 168
36,895 948 202
24,118 580 221
25,749 619 168
39,002 937 342
38,128 916 314
34,534, 34,177 774, 766 360
31,005, 30,469 694, 682 307
33,330 898 326
21,409 463 112
26,590 633 243
28,360 659 214
38,152 1115 188
36,410 1064 235
20,100 587 120
22,053 867 221
14,330 396 141
24,907 858 266
35,939 1158 520
Figure 4. UV-absorption spectra of tested compounds and reference UV filters in chloroform solutions. 
E(1,1)—extinction at 1% concentration and 1 cm optical pathlength.
Absorption spectra of compounds 9 and 10 with two methoxy groups in phenyl ring 
of cinnamoyl residue respectively in 2,4- and 3,4- position differed from other derivatives 
in the tested group demonstrated two peaks of Amax one in UVB and one in UVA II region, 
additionally the values of £max were equally high at both wavelengths which was well 
reflected in the high <E^1 >mean value, especially for compound 9. Ultraviolet absorption 
curve of compound 9 was presented in Figure 4 .
Compounds 15-17 without alkyl or alkoxy linker between xanthone moiety and 
(E)-cinnamoyl residue showed different ultraviolet spectroscopic properties than other 
compounds. The higher values of molar extinction coefficient were observed at 290 nm 
moreover E(1,1) value for compounds 15 (1115) and 16 (1064) with methyl cinnamate sub­
stituent in position 2- or 3- of xanthone ring were comparable to avobenzone. Despite high 
E(1,1) values, these compounds were characterized by relatively low <E1,1>mean parameters. 
This was due to the fact that the absorbance was very high at the initial wavelengths 
but gradually decreased as the wavelength increased (Figure 4). Compound 16 might be 
considered as a strong UVB absorber.
2.4. Photoprotective Activity
The most promising ultraviolet spectroscopic properties showed (E)-cinnamoyl deriva­
tives of 6-metoxy-2-methyl-9H-xanthen-9-one, compounds 8 and 9. They were subjected to 
further tests of photoprotective activity. These compounds were poorly soluble in common 
solvents used in cosmetic products, such as ethanol, polysorbates, triacetin, glycerol, or 
polyoxyethylene glycols. Thus, the selection of an appropriate solvent that would enable 
us to achieve the desired concentration of the UV filter in the final formulation, turned out 
to be impossible. This prompted us to search for a more advanced technological approach 
to incorporate these insoluble compounds into a cosmetic formulation. For that reason, 
the tested compounds were wet milled in a high-energy ball milling process. The milling 
procedure was carried out in the presence of triacetin, and finally a concentrated paste of 
each of the tested compounds was formed. This paste could be easily combined with the 
cream base.
Finally, the formulations loaded with 12.5% (w/w) of compounds 8 or 9 were tested 
using an in vitro method, recommended for the assessment of photoprotective parameters 
in cosmetics products [38]. The absorbance of the samples spread onto PMMA (polymethyl­
methacrylate) plates with a rough surface, imitating the physical characteristic of the skin 
was measured with the SPF-290AS Analyzer. This device was equipped with an integrating 
sphere which collects light scattered by the sample.
Further studies aimed to compare the photoprotective activity of the compounds 8 
and 9. The results were presented in Table 3 and Figure 5 . Compound 8 ((E )-4-methoxy- 
cinnamoyl xanthone derivative) showed high absorption of UVB radiation. The value of 
SPFinvitro of a 12.5% formulation was 14.69 ±  2.25 and exceeded the SPFin vitro coefficient, 
which can be achieved at the maximum allowable concentration by a number of UV protec­
tive substances, such as octocrylene, octinoxate, enzacamene, ensulizole, or iscotrizinol [39]. 
Moreover compound 8 was also active in UVA II region, UVA PF reached 4.92 ±  0.78.
Table 3. Photoprotective activity of compounds 8 and 9 obtained in 12.5% (w/w) cosmetic formulation.
Compound SPFin vitro ±  SD UVA PF ±  SD Ac (nm) UVA/UVB Ratio
8 14.69 ±  2.25 4.92 ±  0.78 345 0.329
9 19.69 ±  0.46 12.64 ±  0.32 381 0.830
Results are presented as mean ±  SD from two independent experiments, at each determination six 
scans were performed.
Figure 5. UV absorption spectra of compounds 8 and 9 obtained in cosmetic formulation at 12.5% 
(w/w) cosmetic formulation applied on polymethylmethacrylate plates. MPF—monochromatic 
protection factor.
Compound 9 possessed an additional methoxy group in 2 - position of phenyl ring 
of (E)-cinnamoyl residue. This additional auuochrome caused significant changes in UV 
absorption properties as compared to compound 8. Compound 9 in a 12.5% formulation 
showeU SPFjn vitro coefficient of 19.69 ±  0.46 and UVA PF of 12.64 ±  0.32. These values were 
similar to tris-biphenyl triazine, which is a broad-spectrum UV-filter and was approved 
for the use in cosmetic products within the European Union in 2014. Couteau et al. tested 
this compound with a similar in vitro method using 50 mg s f  the formulation instead of 
32 nag applied to the PMMA plate in the prenent study. The obtainedvalues of SPFin vitro 
an9 UVA-PF were respectively 21.85 ±  2.70 and 9.64 ±  0.75 [40].
Differences between compound 8 and 9 were also found in two other important 
parameters that characterize sunscreen formulations such as critical wavelength (Ac) and 
U VA /U VB ratio. Critical wavelength is the wavelength for which the section under the 
integrated optical density cunve starting at 290 nm is equal to 90% of the integrate0 sectirn 
between 290 to 400 nm [41] and is in the range from 320 nm which means that UVA 
radiation is not absorbed to 389 nm wden UVA radiation it absorbeU to the same ex9ent 
as UVB [42]. Critical wavelength and U VA/UVB ratio in final sunscreen product should 
be respectively at least 370 nm and 1 /3  (0.33333) to provide a minimum UVE0 and UVA 
protection. For compound 8 critical wavelength and U VA /U VB ratio were 345 nm and 
0.329, respectively, which indicated that it provided little protection against UVA radiation 
and could be considered as a UVB filter. For compound 9 these parameters were 381 nm 
and 0.830, respectively. These findings indicated that compound 9 was a good candidate for 
broad-spectrum UV filter and provided sufficient spectrum of sunscreen product (required 
in EU) without other UV filters in formulation [41]. Additionally, compound 9 might protect 
skin against UVA-induced photoaging, because its critical wavelength exceeded 380 [43].
2.5. Photostability Studies
In order to evaluate functional photostability of compounds 8 and 9, thin layer of 
formulations containing tested compounds applied on PMMA plates were irradiated with 
solar light simulator. The changes in SPFinvitro, UVA PF, Ac and UVA/UVB ratio following 
1 h irradiation corresponding to natural sunlight were investigated. Results were presented
in Figure 6 and Table 4 . The irradiation of formulation with compound 8 caused the change 
in the shape of absorption curve-slight hypsochromic shift and hypochromic effect were 
observed. The decrease of SPFinvitro and UVA PF by 23.95 and 32.8%, respectively, was 
observed. "The value of critical waveleneth shifted by 10 nm from C45 nm to 335 nm, 
additionally the UVA/UVB ratio decreased from 0.339 to 0.201. Io indicrted that irradiation 
mainly contributed to decrease in protection in the UVA region. The decrease of SPFin vitro 
was comparable to that showed by EHMC. In previous study, formulation containing 
EHMC waa irradiated in the seme conditions and % of Initial SPFin vitro was 80.83 [10].
Figure 6. UV absorption spectra of compounds 8 and 9 obtained in pre-irradiation conditions and 1 h post-irradiation with 
solar light simulator conducted at 500 W /m2 in 12.5% (w/w) cosmetic formulations.
Table 4. The changes in photoprotective activity of compounds 8 and 9 after irradiation with solar light simulator at 500 W /m2.
Compound % of Initial % of InitiaC Ac(nm)
UVA/UVB Ratio
SPFin vitro UVA PF Pre-Irradiation Post-Irradiation Pre-Irradiation Post-Irradiation
8 76.05 67.20 345 335 0.339 0.201
9 89.03 82.75 381 380 0.830 0.784
Results are presented as means from two independent experiments, at each determination six scans were performed.
Compound 9 was characterized by much higher photostability. None hypsochromic 
shift was observed, the value of critical wavelength changed only by 1 nm. The decrease 
in SPFinvitro and UVA PF was 10.97 and 17.25%, respectively. Based on the fact that the 
photoprotective activity parumeterr did decrease by more than 20%, compound 9 might be 
considered as a photostable UV filter [44,45]. It is worth mentioning that for avobenzone 
which is most widely used UVA absorber in Europe, USA, Australia, and Japan the decrease 
of UVA PF in cosmetic formulation reaches 41% [46]. Thus, compound 9 may be a good 
alternative for avobenzone.
The changes in photoprotective activity upon irradiation of compounds 8 and 9 most 
likely resulted from the photoisomerization process. Both compounds, similarly to EHMC, 
are (E)-cinnamate derivatives. The main photochemical reaction for these compounds is 
E-Z (trans-cis) isomerization. This photoreaction takes place upon irradiation of UV filters 
containing unsaturated bonds and is considered to be a very efficient way of dispersing the 
absorbed energy [16,47]. In the case of EHMC, both isomers form a photostationary state 
which results in UV absorption loss (30-50% ) because the resulting cis isomer of EHMC 
has almost twice lower extinction coefficient [16]. Compound 9 in comparison to the 8, 
was characterized by higher photostability. It probably was results of the presence of an 
additional methoxy group in ortho position of phenyl ring.
2.6. Safety Assessment
Compound 9, due to its broad-spectrum UV absorbance and excellent photostability, 
and compound 16, a strong UVB absorber with the most promising properties within 
the group of compounds with methyl cinnamate substituent were subjected to in vitro 
preliminary safety assessment. The cytotoxicity of 9 and 16 was evaluated using two 
cell lines of human origin: keratinocytes (HaCaT) and skin fibroblasts (BJ). Additionally, 
hepatocytotoxicity, neurocytotoxicity and cardiocytotoxicity were tested. As reference 
standards, four commercially available UV filters were used including cinnamic acid 
derivatives (octocrylene (OCT) and octinoxate (EHMC)) as well as 3-(4-methyl)benzylidene 
camphor (4-MBC), and benzophenone-1 (BP-1). To investigate the metabolic activity 
of cells incubated in the presence of tested compounds, a MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay was performed. Additionally, estrogenic 
activity of compound 9 was examined in preliminary indirect model involving MCF- 
7 breast cancer cell line, while UV filter benzophenone-2 (BP-2) was used as positive 
control. Additionally, mutagenicity of compounds 8, 9, and 10 was evaluated in vitro using 
microplate Ames assay.
2.6.1. Cytotoxicity Assessment
The cytotoxicity of compounds 9 and 16 was tested on five cell lines: human ker- 
atinocytes, human skin fibroblast, human liver cancer, rat cardiomyoblast and mouse astro­
cytes. The two cell lines delivered from human skin cells: keratinocytes and fibroblasts were 
chosen based on the fact that skin cells are mostly exposed to topically applied cosmetic 
formulations. However, some known UV-filters (e.g., octinoxate and benzophenone-3) 
were proved to cross skin barrier and penetrate to systemic blood stream after topical 
application [5] so we used further cell lines: human liver cancer, rat cardiomyoblast, and 
mouse astrocytes to investigate potential systemic hepatocytotoxicity, cardiocytotoxicity, 
and neurocytotoxicity of the tested compounds, respectively.
The viability of two different types of skin cells grown in presence of the highest 
administered concentration was presented in Figure 7a,b. The cytotoxicity was examined 
after 24 h of incubation with compounds 9 and 16 and reference UV filters (EHMC, OCT). 
Results of cytotoxicity study on human keratinocytes indicated that compounds 9 and 
16, and EHMC in the range of tested concentration (2-50 gM) were deprived of cytotoxic 
activity. A viability of HaCaT cells at the highest tested concentration (50 gM) was above 
78%. In contrast, the viability of human keratinocytes incubated in the presence of reference 
filters significantly decreased (less than 55%). A similar dependence was observed also in 
BJ fibroblast model, where compounds 9 and 16 did not significantly reduce cell viability 
(>80% of control), while incubation with EHMC and OCT resulted in 70.90% and 63.47% 
viable cells, respectively.
The results obtained after incubation of HepG2 cells, mouse astrocytes and rat car- 
diomyoblasts with the compounds 9 and 16, octinoxate, and octocrylene at the highest 
administered (50 gM) concentration were presented in Figure 7c-e . Results of cytotoxicity 
on HepG2 hepatocellular cells indicated that compounds 9 and 16 were safe in the range of 
tested concentrations—viability of cells at 50 gM concentration was 82.79% and 94.26%, 
respectively. Viability of HepG2 cells incubated with EHMC and OCT was 68.87% and 
72.75%, respectively. Compounds 9 and 16 were also deprived of cytotoxic activity against 
mouse astrocytes, the viability of cells was higher than 80%. However reference control 
decreased cellular viability to 59%. Results obtained after incubation of rat cardiomy- 
oblasts with compounds 9 and 16 at 50 gM concentration indicated cell viability at the 
level of 57.02% and 71.25%, respectively, for EHMC and OCT viability was 46.25% and 
42.12%, respectively.
2.6.2. In Vitro Effect on MCF-7 Cells— Preliminary Indirect Model of Estrogenic Activity
Altering of normal function of endocrine system may lead to a variety of health 
problems including reproductive impairments as well as female and male cancers. Some
currently used UV filters (e.g., benzophenones and benzylidene camphor derivatives) were 
proved to influence estrogenic system [48]. Thus, we used preliminary indirect model 
involving MCF-7 breast cancer cell line to investigate estrogenic activity of compound 
9. In this indirect model, potential estrogenic activity may be concluded based on the 
observation of increased cell proliferation after binding of the tested compound with the 
estrogen receptor [48]. We also examined some commercially available UV filters (EHMC, 
OCT, and BP-2). The obtained results were presented in Figure 8. Proliferation analyses 
indicated lack of stimulation effect of tested compounds in MCF-7 breast cancer model. 
In contrast, UV filter BP-2, stimulated proliferati on by over 60%, which was statistically 
significant. This preliminary evaluation indicated lack of estrogenic activity of compound 9.
Figure 7. Viability of human keratinocytes HaCaT (a) and human skin fibroblast (BJ) (b) HepG2 cells (c), mouse astrocytes 
(d) rat cardiomyoblasts H9c2 (e) incubated for 24 h in the presence of compounds 9 and 16, EHMC, and OCT at 50 gM. Cell 
viability was determined using MTT assay. Each experiment was repeated in triplicate. Graphs represent the number of 
viable cells expressed as percent of control (cells not treated with compounds) ±  SD.
Figure 8. Proliferation rate (±SD) of MCF-7 cells incubated with tested compounds at 5 gM. Com­
pound 9, EHMC, and OCT showed lack of proliferation-stimulating effect. BP-2 increased MCF-7 
proliferation by over 60% (*—data significantly different from control, p a 0.05).
2.6.3. Mutagenic Activity
Mutagenic activity is one of the most important endpoints for risk assessment of chem­
ical compounds including drugs and candidate drugs. In the present study, mutagenicity 
of test compounds 8 and 9 was evaluated in vitro using microplate Ames assay. Microplate 
format mutagenicity assay showed that test compounds 8 and 9 did not induce more than 
a twofold induction over the baseline or a dose dependent response, demonstrating the 
absence of mutagenic activity (Table 5) .
Table 5. Mutagenic evaluation of test compounds in the Ames microplate format (MPF) assay.
Positive Wells per Microplate
Salmonella typhimurium
TA98 TA100 TA1535 TA1537
Compound Concentration (mM) FIB*
0.1 0.5 0.1 0.7 0.7
8 0.2 1.1 1.2 0.4 1.0
0.5 1.0 1.3 0.3 0.7
0.1 0.4 0.8 0.1 1.0
9 0.2 0.2 0.7 0.8 0.3
0.5 0.5 0.8 0.7 1.0
Positive control ** 6.4 3.4 14.7 48.0
* FIB—fold induction over baseline (baseline = mean zero-dose control + 1 SD); SD—standard 
deviation. ** Positive controls: 2-nitrofluorene (2-NF) at 2 gg/mL (TA98); 4-nitroquinoline-N-oxide 
(4-NQO) at 0.1 gg/mL (TA100); N4-aminocytidine (N4-ACT) at 100 gg/mL (TA1535); 9-aminoacridine 
(9-AAc) at 15 gg/mL (TA1537).
2.7. Structure-Activity Relationship Studies
(E)-cinnamoyl xanthone derivatives absorbed UV radiation in chloroform solutions in 
the range of 290-375 nm with Amax 290-329, depending on the position of (E)-cinnamoyl 
moiety in xanthone skeleton and on the presence, type and position of auxochrome in both 
xanthone and cinnamoyl moiety. The presence of methoxy group in position 6 of xanthone 
ring contributed to significant improvement of the ultraviolet spectroscopic properties, 
compounds 1 and 2 without 6-methoxy substituent showed worse UV absorption potential 
when compared to their 6-methoxy analogues, compounds 3 and 4. It seemed more 
favorable to introduce a methoxy group than a chlorine atom into the phenyl ring of the 
cinnamoyl residue because it did not contribute to the increase of extinction coefficient, 
but the higher values of <Ei,i>mean was observed for compounds 5 and 7 than 3 and 4. 
The effect of the presence of two methoxy groups in the phenyl ring of the cinnamoyl 
residue was very favorable— it contributed to the appearance of additional Amax as well 
as extension of the UV absorption range into the UVA region and increase of <E11>mean 
value. Moreover, an additional methoxy group in "ortho" position caused improvement of 
photoprotective activity and functional photostability (compound 8 vs. 9). Introduction of 
further methoxygroup in meta position did not result in improvement of UV absorption 
properties (compounds 10 and 11). In compounds 1-13 the position of (E )-cinnamoyl 
substituent in xanthone skeleton did not affect ultraviolet absorption properties. On the 
other hand, in compounds 15-17 the influence of the position of (E)-cinnamoyl substituent 
was significant. Based on the obtained values of extinction coefficient and <E1 ,1 >mean, the 
most favorable was substitution in position 3 of xanthone ring (compound 16).
3. M aterials and Methods
3.1. Chemistry
All reagents used in synthesis of compounds were commercially available of at least 
97% purity. Solvents were commercially available materials of reagent grade. Melting 
points (mp) were uncorrected and were determined using a Buchi SMP-20 apparatus (Buchi 
Labortechnik, Flawil, Switzerland). The 1HNMR (300 MHz) were obtained in CDCl3 with a 
Varian Mercury-VX 300 NMR spectrometer (Varian Inc., Palo Alto, CA, USA) using TMS as 
an internal standard. Spectral data includes chemical shifts in ppm, multiplicities, constant 
couplings in Hz, number of protons, protons' positions. Multiplicities are abbreviated as 
follow: s (singlet), d (doublet), dd (doublet of doublets), ddd (double doublet of doublets), 
ddt (double doublet of triplets), t (triplet), quint (quintet), and m (multiplet). The LC /M S 
system consisted of an Acquity UPLC system (Waters Corporation, Milford, MA, USA) 
coupled to a Waters TQD mass spectrometer (electrospray ionization mode ESI-tandem 
quadrupole). All the L C /M S analyses were carried out using an Acquity UPLC BEH C18, 
1.7 gm, 2.1 x 100 mm2 column. A flow rate of 0.3 m L/m in and a gradient of (5-95)% B over 
10 min and then 100% B over 2 min was used. Eluent A: w ater/0.1%  HCOOH; eluent B: 
acetonitrile/0.1% HCOOH. LC /M S data were obtained by scanning the first quadrupole in 
0.5 s in a mass range from 50 to 1000 Da; 8 scans were added to produce the final spectrum.
3.1.1. Preparation of Substrates for Syntheses
Substrates used in the synthesis of compounds 1-17 were obtained according to pre­
viously published procedures. Their physicochemical data was consistent with available 
literature. The first step was the modified Ullmann's condensation [49] of the commercially 
available substrates, i.e., appropriate sodium salts of 2 -chlorobenzoic acid reacted with 
cresol, 2- or 4-methoxyphenol or phenol (also as sodium salts). The condensation was per­
formed at the temperature of 200-210 °C in paraffin oil with the catalytic amount of Cu and 
Cu2O. Then by cyclization (2 to 4 h) of condensation products using concentrated sulfuric 
acid obtained a corresponding 9H -xanthen-9-ones: 4-methyl-9H -xanthen-9-one [25,50], 
6-chloro- or 7-chloro-2-methyl-9H -xanthen-9-one [27], 3-chloro-5-methyl-9H -xanthen-9- 
one [19], 3-chloro-9H-xanthen-9-one [51]. 2- and 4-Hydroxy-9H-xanthen-9-one [28,31] were 
products of demethylation in cyclization process. 3-Methoxy- [30], 6-methoxy-2-methyl- 
9H-xanthen-9-one [52] and 3-methoxy-5-methyl-9H-xanthen-9-one [19] were obtained by 
methanolysis of appropriate 3-chloro and 6-chloro substituted 9H -xanthen-9-ones. Then 
appropriate methyl derivatives of 9H -xanthen-9-one were subject to bromination with 
N-bromosuccinimide in the presence of benzoyl peroxide catalyst in tetrachloride [19,25,26].
3-Hydroxy-9H -xanthen-9-one was obtained by demethylation of 3-metoxy-9H -xanthen-9- 
one using 80% H2SO4 [53]. 2-(3-Bromopropoxy)-9H -xanthen-9-one was prepared in the 
two-step reaction from 2-hydroxy-9H -xanthen-9-one using 3-chloropropanol and phospho­
rus tribromide [32] (Schemes S1 and S2 Supplementary Materials).
3.1.2. Preparation of Compounds 1-13
A mixture of appropriate bromo-substituted xanthone derivative (0.01 mol), appro­
priate (E)-cinnamic acid derivative (0.011 mol), and potassium carbonate (0.007 mol) was 
stirred in DMF (20 mL) for 8 to 10 h at room temperature. Then the mixture was poured 
into ice and obtained solid was filtered and washed with 5% sodium bicarbonate solution 
and water. After drying crude product was crystallized from toluene: heptan (2 /1 )  with 
the addition of silica gel. The yield of reaction was 64 to 76%.
3.1.3. Preparation of Compound 14
A mixture of 2-(3-bromopropoxy)-9H-xanthen-9-one (0.01 mol), trans-4-methoxycinnamic 
acid (0.011 mol), and potassium carbonate (0.007 mole was stirred in DMF (20 mL) for 8 to 
10 h at room temperature. Then the mixture was poured into ice and obtained solid was 
filtered and washed with 5% sodium bicarbonate solution and water. After drying crude
product was crystallized from toluene: heptan (2 /1 ) with the addition of silica gel. The
yield of reaction was 63%.
3.1.4. Preparation of Compounds 15-17
A mixture of appropriate 2-, 3- or 4-hydroxy-9H-xanthen-9-one derivative (0.01 mol), 
0.015 mole of (E)-cinnamoyl chloride (0.015 mol), and potassium carbonate (0.007 mol) was 
stirred in DMF (20 mL) for 6 to 8 h at room temperature. Then the mixture was poured into 
ice and obtained solid was filtered and washed with 5% sodium bicarbonate solution and 
water. After drying crude product was crystallized from toluene: heptan (2 /1 ) with the 
addition of silica gel. The yield of reaction was 64 to 70%.
3.1.5. Physiochemical Properties of Tested Compounds
(9-oxo-9H -xanthen-4-yl)methyl (E )-3-(2-chlorophenyl)acrylate (1 ) was obtained as 
white solid (yield 64%), MW  = 390.82, mp 156-157 °C, 1H NMR (300 MHz, CDCl3) 6
8.40-8.30 (m, 2H), Ar-H1, Ar-H8, 8.20 (dd, J  =  16.0, 0.7 Hz, 1H, =CH-), 7.86 (ddd, J  =  7.3,
1.7, 0.8 Hz, 1H, Ar-H3), 7.76 (ddd, J  = 8.7, 7.1,1.8 Hz, 1H, Ar-H6), 7.67-7.52 (m, 2H, Ar-H7, 
Cyn-H6), 7.51-7.35 (m, 3H, Ar-H2, Cyn-H3, Cyn-H4), 7.35-7.20 (m, 2H, Ar-H5, Cyn-H5), 
6.52 (d, J  =  16.0 Hz, 1H, -CH=), 5.67 (s, 2H, -CH2-), ESI-M S (m /z): [M + H ]+ calcd. for 
C23H 15ClO4, 391.82, found, 391.11 100%.
(9-oxo-9H -xanthen-4-yl)methyl (E )-3-(4-chlorophenyl)acrylate (2) was obtained as 
white solid (yield 66%), MW = 390.82, mp 177-178 °C, 1H NMR (300 MHz, CDCl3) 6 8.34 
(dt, J  =  8 .0 ,1 .6  Hz, 2H, Cyn-H2, Cyn-H6), 7.83 (dd, J  =  7 .3 ,1 .7  Hz, 1H, Ar-H8), 7.79-7.61 
(m, 2H, Ar-H1, =CH-), 7.54 (dd, J  =  8.5, 1.1 Hz, 1H, Ar-H3), 7.50-7.26 (m, 6H, Ar-H7, 
Ar-H6, Ar-H5, Ar-H2, Cyn-H3, Cyn-H5), 6.49 (d, J  = 16.0 Hz, 1H, -CH=), 5.63 (s, 2H, -CH2-), 
ESI-MS (m/z): [M + H]+ calcd. for C23H 15ClO4, 391.82, found, 391.11 98.46%.
(6-methoxy-9-oxo-9H-xanthen-4-yl)methyl (E)-3-(2-chlorophenyl)acrylate (3) was ob­
tained as white solid (yield 69%), MW = 420.85, mp 160-162 °C, 1H NMR (300 MHz, CDCb) 
6 8.32 (dd, J  = 8.0,1.8 Hz, 1H, Ar-H1), 8.27-8.10 (m, 2H, =CH-, Ar-H7), 7.81 (ddd, J  = 7.3,1.7, 
0.8 Hz, 1H, Ar-H3), 7.66-7.56 (m, 1H, Ar-H8), 7.48-7.19 (m, 4H, Ar-H2, Cyn-H3, Cyn-H4, 
Cyn-H5), 7.00-6.89 (m, 2H, Ar-H5, Cyn-H6), 6.52 (d, J  =  16.0 Hz, 1H, -CH=), 5.64 (s, 2H, 
-CH2-), 3.94 (s, 3H, -OCH3), ESI-MS (m/z): [M + H]+ calcd. for C24H17ClO5, 421.85, found, 
421.15 98.02%.
(6-methoxy-9-oxo-9H -xanthen-4-yl)methyl (E )-3-(4-chlorophenyl)acrylate (4) was ob­
tained as white solid (yield 66%), MW = 420.85, mp 202-203 °C, 1H NMR (300 MHz, CDCl3) 
6 8.33 (dd, J  = 8.0,1.8 Hz, 1H, Ar-H1), 8.25 (d, J  = 8.8 Hz, 1H, Cyn-H5), 7.81 (dd, J  = 7.4,1.8 
Hz, 1H, Ar-H2), 7.72 (d, J  = 16.0 Hz, 1H, =CH-), 7.46 (d, J  = 8.5 Hz, 2H, Cyn-H2, Cyn-H6), 
7.40 (d, J  = 7.6 Hz, 1H, Ar-H8), 7.36 (d, J  = 3.1 Hz, 1H, Cyn-H3), 7.34 (s, 1H, Ar-H5), 6.98 (d, 
J  =  2.4 Hz, 1H, Ar-H7), 6.96-6.91 (m, 1H, Ar-H3), 6.50 (d, J  =  16.0 Hz, 1H, -CH=), 5.63 (s, 
2H, -CH2-), 3.94 (s, 3H, -OCH3), ESI-M S (m /z): [M + H ]+ calcd. for C24H 17ClO5, 421.85, 
found, 421.15 100%.
(6-methoxy-9-oxo-9H -xanthen-4-yl)methyl (E )-3-(2-methoxyphenyl)acrylate (5) was 
obtained as white solid (yield 68%), MW = 416.43, mp 164-165 °C, 1H NMR (300 MHz, 
CDCl3) 6 8.32 (dd, J  = 8.0,1.7 Hz, 1H, Ar-H1), 8.27-8.21 (m, 1H, Ar-H8), 8.09 (d, J  = 16.2 Hz, 
1H, =CH-), 7.85-7.79 (m, 1H, Cyn-H6), 7.51 (dd, J  = 7.7,1.7 Hz, 1H, Ar-H3), 7.42-7.31 (m, 2H, 
Ar-H2, Cyn-H4), 6.99-6.88 (m, 4H, Ar-H7, Ar-H5, Cyn-H3, Cyn-H5), 6.62 (d, J  = 16.1 Hz, 
1H, -CH=), 5.62 (s, 2H, -CH2-), 3.93 (s, 3H, -OCH3), 3.87 (s, 3H, -OCH3), ESI-MS (m/z): [M 
+ H]+ calcd. for C25H20O6, 417.43, found, 417.16 100%.
(6-methoxy-9-oxo-9H -xanthen-4-yl)methyl (E )-3-(3-methoxyphenyl)acrylate (6) was 
obtained as white solid (yield 67%), MW = 416.43, mp 153-154 °C, 1H NMR (300 MHz, 
CDCl3) 6 8.32 (dd, J  =  8.0, 1.8 Hz, 1H, Ar-H1), 8.31-8.18 (m, 1H, Ar-H8), 7.81 (ddd, 
J  = 7.4,1.6, 0.8 Hz, 1H, Ar-H3), 7.74 (d, J  =  16.0 Hz, 1H, =CH-), 7.44-7.33 (m, 1H, Cyn- 
H4), 7.33-7.22 (m, 1H, Ar-H2), 7.12 (ddt, J  = 7 .6 ,1 .5 ,0 .7  Hz, 1H, Cyn-H6), 7.04-6.88 (m, 4H, 
Ar-H5, Ar-H7, Cyn-H2, Cyn-H5), 6.51 (d, J  = 16.0 Hz, 1H, -CH=), 5.62 (s, 2H, -CH2-), 3.93
(s, 3H, -OCH3), 3.81 (s, 3H, -OCH3), ESI-MS (m/z): [M + H]+ calcd. for C25H20O6, 417.43, 
found, 417.09 100%.
(6-methoxy-9-oxo-9H -xanthen-4-yl)methyl (E )-3-(4-methoxyphenyl)acrylate (7) was 
obtained as white solid (yield 71%), MW = 416.43, mp 167-168 °C, 1H NMR (300 MHz, 
CDCl3) 6 8.33 (dd, J  =  8 .0 ,1 .7  Hz, 1H, Ar-H1), 8.25 (dd, J  =  8.6, 0.7 Hz, 1H, Ar-H8), 7.82 
(dd, J  =  7.4, 1.8 Hz, 1H, Ar-H7), 7.74 (d, J  =  16.0 Hz, 1H, =CH-), 7.49 (d, J  =  8.8 Hz, 2H, 
Cyn-H2, Cyn-H6), 7.39 (t, J  = 7.7 Hz, 1H, Ar-H2), 6.98 (d, J  = 2.4 Hz, 1H, Ar-H3), 6.95 (s, 1H, 
Ar-H5), 6.90 (d, J  = 8.8 Hz, 2H, Cyn-H3, Cyn-H5), 6.40 (d, J  = 15.9 Hz, 1H, -CH=), 5.62 (s, 
2H, -CH2-), 3.94 (s, 3H, -OCH3), 3.83 (s, 3H, -OCH3), ESI-MS (m /z): [M + H ]+ calcd. for 
C25H20O6, 417.43, found, 417.20 100%.
(6-methoxy-9-oxo-9H -xanthen-2-yl)methyl (E )-3-(4-methoxyphenyl)acrylate (8) was 
obtained as white solid (yield 71%), MW = 416.43, mp 169-171 °C, 1H NMR (300 MHz, 
CDCl3) 6 8.38-8.33 (m, 1H, Ar-H1), 8.24 (d, J  =  8.9 Hz, 1H, Ar-H8), 7.77-7.72 (m, 1H, 
Ar-H3), 7.69 (d, J  = 15.9 Hz, 1H, =CH-), 7.51-7.43 (m, 3H, Ar-H4, Cyn-H6, Cyn-H2), 6.96 (d, 
J  = 2.4 Hz, 1H, Ar-H5), 6.93 (d, J  = 2.4 Hz, 1H, Ar-H7), 6.91-6.83 (m, 2H, Cyn-H3, Cyn-H5),
6.40-6.32 (m, 1H, -CH=), 5.33 (s, 2H, -CH2-), 3.93 (s, 3H, -OCH3), 3.82 (s, 3H, -OCH3), 
ESI-MS (m/z): [M + H]+ calcd. for C25H20O6, 417.43, found, 417.23 99.14%.
(6-methoxy-9-oxo-9H -xanthen-2-yl)methyl (E )-3-(2,4-dimethoxyphenyl)acrylate (9) 
was obtained as white solid (yield 73%), MW = 446.46, mp 194-195 °C, 1H NMR (300 MHz, 
CDCl3) 6 8.40-8.34 (m, 1H, Ar-H1), 8.25 (d, J  =  8.9 Hz, 1H, Cyn-H5), 7.95 (d, J  =  16.1 Hz, 
1H, =CH-), 7.75 (dd, J  = 8.6, 2.3 Hz, 1H, Ar-H3), 7.45 (t, J  = 8.4 Hz, 2H, Ar-H4, Ar-H8), 6.95 
(dd, J  = 8.9, 2.4 Hz, 1H, Ar-H7), 6.89 (d, J  = 2.4 Hz, 1H, Ar-H5), 6.56-6.45 (m, 2H, Cyn-H3, 
-CH=), 6.44 (d, J  = 2.4 Hz, 1H, Cyn-H6), 5.33 (s, 2H, -CH2-), 3.94 (s, 3H, -OCH3), 3.86 (s, 3H, 
-OCH3), 3.83 (s, 3H, -OCH3), ESI-MS (m/z): [M + H]+ calcd. for C26H22O7, 447.46, found, 
447.20 98.69%.
(6-methoxy-9-oxo-9H-xanthen-2-yl)methyl (E)-3-(3,4-dimethoxyphenyl)acrylate (10) 
was obtained as white solid (yield 76%), MW = 446.46, mp 189-190 °C, 1H NMR (300 MHz, 
CDCl3) 6 8.41-8.34 (m, 1H, Ar-H1), 8.25 (d, J  = 8.9 Hz, 1H, Ar-H8), 7.74 (dd, J  = 8.6, 2.3 Hz, 
1H, Ar-H3), 7.68 (d, J  =  15.9 Hz, 1H, =CH-), 7.51-7.42 (m, 1H, Ar-H7), 7.15-7.02 (m, 2H, 
Ar-H4, Ar-H5), 7.00-6.92 (m, 1H, Cyn-H5), 6.92-6.81 (m, 2H, Cyn-H2, Cyn-H6), 6.37 (d, 
J  = 15.9 Hz, 1H, -CH=), 5.34 (s, 2H, -CH2-), 3.96-3.85 (m, 9H, -OCH3, -OCH3, -OCH3)., 
ESI-MS (m/z): [M + H]+ calcd. for C26H22O7, 447.46, found, 447.14 96.99%.
(6-methoxy-9-oxo-9H -xanthen-2-yl)methyl (E)-3-(2,3,4-trimethoxyphenyl)acrylate (1 1 ) 
was obtained as white solid (yield 68%), MW = 476.48, mp 188-190 °C, 1H NMR (300 MHz, 
CDCl3) 6 8.39 (dd, J  =  2.3, 0.6 Hz, 1H, Ar-H1), 8.26 (d, J  =  8.9 Hz, 1H, Ar-H8), 7.74 (dd, 
J  = 8.6, 2.3 Hz, 1H, Ar-H3), 7.65 (d, J  = 15.9 Hz, 1H, =CH-), 7.48 (d, J  = 8.6 Hz, 1H, Ar-H7), 
7.29-7.23 (m, 1H, Ar-H4), 7.01-6.93 (m, 1H, Cyn-H2), 6.90 (d, J  = 2.4 Hz, 1H, Ar-H5), 6.76 (s, 
1H, Cyn-H6), 6.42 (d, J  = 15.9 Hz, 1H, -CH=), 5.35 (s, 2H, -CH2-), 3.94 (s, 3H, -OCH3), 3.88 
(d, J  = 2.0 Hz, 9H, -OCH3, -OCH3, -OCH3), ESI-MS (m /z): [M + H ]+ calcd. for C27H24O8, 
477.48, found, 477.18 100%.
(6-methoxy-9-oxo-9H-xanthen-2-yl)methyl (E)-2,3-diphenylacrylate (12) was obtained 
as white solid (yield 72%), MW = 462.50, mp 171-172 °C, 1H NMR (300 MHz, CDCb) 6 ppm 
8.30 (d, J  = 2.34 Hz, 1H, Ar-H1), 8.24 (d, J  = 8.79 Hz, 1H, Ar-H8), 7.89 (s, 1H, =CH-), 7.65 (dd, 
J  = 8.50,2.05 Hz, 1H, Ar-H3), 7.33-7.44 (m, 4H, Ar-H4, Cyn-H3, Cyn-H5, Ph-H4), 7.11-7.27 
(m, 5H, Cyn-H4, Ph-H2, Ph-H3, Ph-H2, Ph-H6), 7.03-7.08 (m, 2H, Cyn-H2, Cyn-H6), 6.94 
(dd, J  = 8.79, 2.34 Hz, 1H, Ar-H7), 6.87 (d, J  = 2.34 Hz, 1H, Ar-H5), 5.35 (s, 2H, -CH2-), 3.92 
(s, 3H, -OCH3), ESI-MS (m/z): [M + H]+ calcd. for C30H22O5, 463.50, found, 463.22 98.64%.
(7-chloro-9-oxo-9H -xanthen-2-yl)methyl (E )-3-(4-methoxyphenyl)acrylate (13) was 
obtained as white solid (yield 68%), MW = 420.85, mp 160-161 °C, 1H NMR (300 MHz, 
CDCl3) 6 8.38-8.26 (m, 2H, Ar-H8, Ar-H1), 7.80 (dd, J  = 8.7, 2.3 Hz, 1H, Ar-H3), 7.76-7.62 
(m, 2H, Ar-H5, =CH-), 7.58-7.42 (m, 4H, Ar-H4, Ar-H6, Cyn-H2, Cyn-H6), 6.96-6.85 (m, 2H, 
Cyn-H3, Cyn-H5), 6.37 (d, J  = 15.9 Hz, 1H, -CH=), 5.34 (s, 2H, -CH2-), 3.84 (s, 3H, -OCH3), 
ESI-MS (m/z): [M + H]+ calcd. for C24H 17ClO5, 421.85, found, 421.08 98.32%.
3-((9-oxo-9H -xanthen-2-yl)oxy)propyl (E )-3-(4-methoxyphenyl)acrylate (14) was ob­
tained as white solid (yield 63%), MW  =  430.46, mp 139-140 °C, 1 H NMR (300 MHz, 
CDCl3) 6 8.39-8.29 (m, 1H, Ar-H8), 7.77-7.68 (m, 2H, Ar-H1, Ar-H7), 7.65 (d, J  = 16.0 Hz, 
1H, =CH-), 7.53-7.41 (m, 4H, Ar-H3, Ar-H5, Cyn-H2, Cyn-H6), 7.41-7.29 (m, 2H, Ar-H4, 
Ar-H6), 6.94-6.83 (m, 2H, Cyn-H3, Cyn-H5), 6.39-6.26 (m, 1H, -CH=), 4.42 (t, J  =  6.2 Hz, 
2H, -CH2-O), 4.23 (t, J  = 6.1 Hz, 2H, O-CH2-), 3.82 (s, 3H, -OCH3), 2.24 (quint, J  = 6.2 Hz, 
2H, -CH2-), ESI-MS (m/z): [M + H ]+ calcd. for C26H22O6, 431.46, found, 431.25 100%.
9-oxo-9H-xanthen-2-yl cinnamate (15) was obtained as white solid (yield 70%), MW = 342.35, 
mp 162-164 °C, 1 H NMR (300 MHz, CDCl3) 6 ppm 8.35 (dd, J  = 7.91,1.47 Hz, 1H, Ar-H8), 
8.09-8.13 (m, 1H, Ar-H1), 7.92 (d, J  = 15.82 Hz, 1H, =CH-), 7.71-7.79 (m, 1H, Ar-H6), 7.62 
(dd, J  =  6.45, 2.93 Hz, 2H, Cyn-H2, Cyn-H6), 7.55-7.58 (m, 2H, Ar-H4, Ar-H5), 7.52 (d, 
J  =  7.62 Hz, 1H, Ar-H3), 7.42-7.47 (m, 3H, Ar-H7, Cyn-H3, Cyn-H5), 7.37-7.42 (m, 1H, 
Cyn-H4), 6.67 (d, J  =  15.82 Hz, 1H, -CH=), ESI-M S (m/z): [M + H]+ calcd. for C22H 14O4, 
343.35, found, 343.12 100%.
9-oxo-9H-xanthen-3-yl cinnamate (16) was obtained as white solid (yield 64%), MW = 342.35, 
mp 173-174 °C, 1 H NMR (300 MHz, CDCl3) 6 ppm 8.39 (d, J  = 8.79 Hz, 1H, Ar-H1), 8.35 
(dd, J  = 7.91,1.47 Hz, 1H, Ar-H8), 7.93 (d, J  = 16.41 Hz, 1H, =CH-), 7.58-7.77 (m, 3H, Ar-H6, 
Cyn-H2, Cyn-H6), 7.36-7.53 (m, 6H, Ar-H4, Ar-H7, Ar-H5, Cyn-H3, Cyn-H4, Cyn-H5), 7.22 
(dd, J  = 8.79,2.34 Hz, 1H, Ar-H2), 6.66 (d, J  = 15.82 Hz, 1H, -CH=), ESI-MS (m/z): [M + H]+ 
calcd. for C22H 14O4, 343.35, found, 343.12 100%.
9-oxo-9H-xanthen-4-yl cinnamate (17) was obtained as white solid (yield 67%), MW = 342.35, 
mp 192-193 °C, 1 H NMR (300 MHz, CDCl3) 6 8.40-8.29 (m, 1H, Ar-H8), 8.29-8.21 (m, 1H, 
Ar-H1), 8.00 (d, J  = 16.0 Hz, 1H, =CH-), 7.76-7.54 (m, 4H, Ar-H6, Ar-H3, Cyn-H3, Cyn-H5), 
7.52-7.33 (m, 6H, Ar-H7, Ar-H5, Ar-H2, Cyn-H2, Cyn-H6, Cyn-H4), 6.79 (d, J  =  16.0 Hz, 
1H, -CH=), ESI-MS (m/z): [M + H]+ calcd. for C22H 14O4, 343.35, found, 343.12 100%.
3.2. Evaluation o f Lipophilicity Parameter RM0
Reversed-phase thin-layer chromatography (RP-TLC) was performed on aluminum 
sheets 20 x 20 cm2 coated with silica gel RP-18 F254 (Merck, Darmstadt, Germany). The 
mobile phases constituted mixtures of methanol and 100 mM potassium-phosphate buffer 
(pH = 7.4), with the methanol content between 95 and 65% (v/v). The tested compounds 
were dissolved separately in chloroform (1 m g/m L) and 5 gL of solutions were transferred 
on the sheets. Chromatographic chambers were saturated with mobile phase for 1 h at room 
temperature before developing the sheets. The spots were observed in UV light. For each 
concentration of methanol Rf values were calculated and mean values are reported from two 
independent experiments (Table S 1  Supplementary material). RM values were calculated 
from the experimental Rf using equation: RM = log(1/R f — 1) (Table S2 Supplementary 
material). The calculated values of RM were extrapolated for 0% methanol concentration 
(Table 1) [33,34].
3.3. Ultraviolet Spectroscopy
Spectra with a scan range of 290-400 nm were recorded in 30 gM chloroform solutions, 
in 1 cm path length, 1.5 mL quartz cuvettes on a U-2800 double beam spectrophotometer 
(Hitachi, Tokyo, Japan) controlled by UV Solution version 2.2 software. The molar extinc­
tion coefficient at maximum absorption (emax) of tested compounds was determined in 
chloroform as the slope of the linear regression of absorbance vs. concentration of tested 
compound (from 2.5 to 30 gM). E(1,1) coefficient was calculated from the formula:
<E1 ,1 >mean value is a mean value of the specific extinction over the spectral range from 
290 to 400 nm.
3.4. Photoprotective Activity
3.4.1. Preparation of Simple Cosmetic Formulations
To assess the activity of compounds 8 and 9 as UV filters, they were incorporated 
into a macrogol cream. This cream was made of PEG 400 and PEG 1500 mixed at 70 °C in 
1:1 (w /w) ratio. Then, two concentrates, containing 50% (w /w) of the tested compounds 
8 or 9 were prepared with the aim to combine them with this macrogol cream. First, the 
tested compounds were mixed with triacetin in 1:1 (w/w) ratio. Each mixture was wet 
milled using a high-energy planetary ball mill (Pulverisette 7 classic line, Fritsch, Germany). 
The total milling time was 12 h, but to avoid the overheating of the sample, the milling 
procedure was performed in cycles, i.e., the milling periods of 20 min were followed by the 
pause periods of 10 min. The rotation speed of the solar disc was kept at 400 rpm. After 
such processing, the concentrates in the form of a white paste were obtained. Then, each of 
these concentrates was mixed with the macrogol cream at 70 ° C in three wt. ratios, namely 
1:3,1:5.25 or 1:9.
3.4.2. In Vitro Photoprotection Study
In vitro photoprotective activity of compounds 8 and 9 was evaluated according to 
EN ISO 24443:2012 [38] with slight modifications. 32.5 mg of formulation with tested 
compound was spread onto roughened polymethylmethacrylate plate (PMMA) purchased 
from Schonberg GmbH (Hamburg, Germany) with the application area 25 cm2 and 5 gm 
roughness value to simulate the skin surface. After 30 min in the dark in vitro absorbance 
of samples was measured from 290 to 400 nm with 1 nm steps by reflectance spectropho­
tometry. SPF-290AS Analyser (Solar Light Company, Glenside, PA, USA) equipped with 
integrating sphere coupled with a WinSPF version 4.4 software was used. For each sample 
two plates were prepared, absorbance measures were performed on 6 different positions of 
the plate. The results were expressed as an average of data from 12 scans.
3.5. Photostability Study
To evaluate functional photostability of compounds 8 and 9 PMMA plates with tested 
compounds was irradiated with solar light simulator (Suntest CPS+, Atlas, Linsengericht, 
Germany) equipped with an optical filter cutting off wavelengths shorter than 290 nm and 
IR-block filter to neutralize thermal effects. The light source emission was maintained at 
500 W /m 2 and irradiation procedure was conducted for 1 h which corresponds to cumula­
tive dose of ultraviolet radiation 218 k J/m 2 and is consistent with previous studies [10,54]. 
The UV absorption spectrum of the samples and photoprotective activity parameters were 
analysed post-irradiation and compared with pre-irradiation results. All analyses were 
performed in duplicates.
3.6. In Vitro Viability Assessment
Skin fibroblast BJ (ATCC CRL 2522), keratinocytes cell line HaCaT (Sigma Aldrich) 
human liver cancer HepG2 cell line (ATCC HB8065), rat cardiomyoblast H9c2 (ATCC 
CRL1446), and mouse astrocytes (ATCC, CRL2541) were cultured in standard conditions 
(37 °C, 5% CO2, 95% humidity) in appropriate culture medium (according to manufacturer 
procedure), supplemented with 10% fetal bovine serum (FBS, Gibco) and antibiotics (1% 
streptomycin/penicillin mixture; Sigma-Aldrich). Cells were seeded at density of 2 x 104 
(BJ, HaCaT) on 96-well plates. After 24 h cells were treated with increasing doses of 
compounds and incubated for additional 24 h. Following the incubation, MTT reagent 
(Sigma-Aldrich, Darmstadt, Germany) was added to each well and after 4 h incubation, the 
medium was aspirated, and the formazan produced in the cells appeared as dark crystals 
in the bottom of the wells. Next, DMSO (dissolving solution) was added to each well. Then, 
the absorbance of solution was determined at 570 nm (A570) on plate reader (Spectra iD3 
Max, Molecular Devices; San Jose, CA, USA). Viability (% of control) was determined by 
dividing A570 of experimental wells by of A570 of control wells x 100%. Data from the 
cytotoxicity tests were subjected to one-way analysis of variance, followed by Dunnett's
test using GraphPad Prism 7.0 Software (GraphPad Software Inc., San Diego, CA, USA). 
Values of p < 0.05 were considered to be statistically significant.
3.7. Estrogenic Activity
Estrogenic activity of tested compounds was investigated by study of their influence 
on estrogen-dependent MCF-7 breast cancer cell line proliferation. Cells were seeded 
into 24-wells plates in density of 40,000 per well. After 24 h, cells were washed twice 
with PBS and fresh, estrogen- and phenol red-free medium (DMEM low-glucose; 2.5% 
Charcoal Stripped FBS; 2 mM glutamine; Sigma Aldrich, Darmstadt, Germany) was added. 
Then cells were incubated with tested compounds and benzophenone-2 (BP-2; Sigma 
Aldrich, Darmstadt, Germany) to final concentration of 5 gM. After 120 h incubations, 
cells proliferation was determined with crystal violet assay. Briefly, cells were washed 
with PBS and fixed with 3.7% formaldehyde. Then, crystal violet solution was added for 
10 min. After incubation, solution was removed, and cells were washed five times with 
PBS. Crystal violet was extracted from cells using destaining solution (1.33% citric acid, 
1.09% sodium citrate in water/methanol (1:1) solution) and absorbance of the solution was 
determined at 570 nm (A570). Proliferation rate was determined by dividing the A570 of 
experimental wells by the A570 of control wells x 100%.
3.8. Mutagenicity Assay Procedure
Test compounds mutagenic effects were evaluated using the Ames microplate format 
(MPF) mutagenicity assay with Salmonella typhimurium TA98, TA100, TA1535 and TA1537 
strains (Xenometrix, Allschwil, Switzerland). These strains meet the requirements of 
the Organization for Economic Cooperation and Development (OECD) guideline 471 for 
testing of chemicals [55]. Culture media, positive control chemicals, and tester strains were 
provided in the kit. TA100 and TA1535 strains are used to detect mutagens that cause 
base-pair substitutions, while TA98 and TA1537 detect frameshift mutations.
MPF assay is a modification of the traditional Salmonella test [56,57]. During the 
assay, bacteria are exposed to a test compound in a medium containing histidine to support 
cell divisions. Then, the cultures are diluted using indicator medium which lacks the 
required amino acid and selects for prototrophic reversion, and aliquoted into 48 wells of 
a 384-well plate. Within two days, bacteria that have undergone reversion to amino acid 
prototrophy will form colonies. The indicator medium turns yellow as the pH drops as 
a result of catabolic activity of revertant bacteria that grow in the absence of the required 
amino acid [58].
In the present study bacterial cultures were grown overnight (16 h) in growth medium 
and then exposed to test compounds (8 and 9) in 24-well plates for 90 min at 37 ° C with 
constant shaking. Compounds were tested at final concentrations of 0.1, 0.2 , and 0.5 mM. 
After preincubation, the cultures were diluted in the indicator medium and the contents of 
each 24-well culture were transferred to 48 wells on a 384-well plate. Upon completion of 48 
h incubation period, yellow revertant wells were counted for each dose and compared with 
the number of spontaneous revertants obtained with the negative control. The standard 
positive controls for the Ames MPF assay were 2-nitrofluorene (2-NF) at 2 gg/m L (TA98);
4-nitroquinoline-N-oxide (4-NQO) at 0.1 gg/m L (TA100); N4-aminocytidine (N4-ACT) at 
100 gg/m L  (TA1535) and 9-aminoacridine (9-AAc) at 15 gg/m L  (TA1537), whereas pure 
DMSO was used as a negative control. Each dose was done in triplicate [58- 61].
Two criteria were applied to evaluate mutagenicity assay results such as the fold 
increase in the number of positive wells over the solvent control baseline (FIB), and the 
dose dependent response. FIB was calculated by dividing the mean number of positive 
wells at each dose by the solvent control at baseline (mean of negative control plus 1 SD). 
W hen an induction of more than twofold relative to the baseline at more than one dose 
with a dose-response was observed the sample was considered positive, whereas when no 
response >2 times the baseline and no dose-response was stated the sample was classified 
as negative in the assay [57- 59].
4. Conclusions
We designed and synthetized 17 novel structures containing two chromophores: 
xanthone and (E )-cinnamoyl. Among the presented group of compounds, there were 
potential UVA and UVB filters, their Amax was in the range from 290 to 329 nm, additionally 
compounds were characterized by high extinction coefficient and favorable lipophilic- 
ity predisposing to cumulate in stratum corneum. The most promising compound in 
the tested series was compound 9 ((6-methoxy-9-oxo-9H -xanthen-2-yl)methyl (E )-3-(2,4- 
dimethoxyphenyl)acrylate). It showed two peaks of Amax, one in UVB and one in UVA 
II region. After milling, it was loaded into a simple cream base at the concentration of 
12.5% and showed very beneficial photoprotective properties (SPFin vitro 19.69 ±  0.46, UVA 
PF 12.64 ±  0.32), which were comparable to tris-biphenyltiazine. Moreover, high value 
of critical wavelength (381 nm) indicated that compound 9 was a good candidate for a 
broad-spectrum UV filter that may protect skin against UVA-induced photoaging. Com­
pound 9 in high concentration (50 gM) was deprived of cytotoxic activity toward human 
keratinocytes, human skin fibroblasts, mouse astrocytes and hepatoma cells. Compound 9 
showed no estrogenic activity in MCF-7 breast cancer model. It also showed no mutagenic 
activity, the performed Ames test indicated that compound 9 was not base substitution or 
frameshift mutagen. According to the results of performed research it can be concluded, 
that in the group of xanthone derivatives new UV filters may be identified.
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